Dr Ved Srivastava is Vice President of Peptide Chemistry at Intarcia Therapeutics. Prior to that he co-founded and was Vice President of Chemistry at Phoundry Pharmaceuticals, a peptide therapeutic discovery company that was acquired by Intarcia. Prior to Phoundry, he was the Head of Peptide Chemistry at GlaxoSmithKline. Ved spent several years in a leadership role with Amylin Pharmaceuticals, where he focused on the discovery and development of novel peptide hormones for diabetes, obesity and neuropsychiatric therapies. He has participated in the development and commercialization of Symlin™, Byetta™ and Bydureon™, first-in-class medicines for the treatment of diabetes.
Ved has more than 25 years of experience with expertise in drug discovery and development in the area of metabolic diseases, the central nervous system and inflammation, with major emphasis in peptide medicinal chemistry, chemistry manufacturing and control and peptide drug delivery. He has numerous scientific disclosures, including patents, scientific articles and invited lectures.
Ved is the editor of two other books, Peptide 2015 (American Peptide Society) and Comprehensive Medicinal Chemistry III, Volume 7. Biologics Medicine (Elsevier). He is an editorial board member of The FASEB Journal (the Federation of American Societies for Experimental Biology); and an editorial advisory board member of the Current Protein & Peptide Science journal.
Ved serves in the governance and leadership team of the American Peptide Society and the American Chemical Society and other peptide societies. Ved is also an appointed member of the BIO1 Peptides and Insulins Expert Committee and the Therapeutic Peptides Expert Panel of the US Pharmacopeial Convention in partnership with the US Food and Drug Administration. He earned a PhD in organic chemistry from the University of Lucknow, India, and had subsequent postdoctoral appointments at the University of Georgia and the University of Colorado School of Medicine.
Ved Srivastava
Intarcia Therapeutics, NC, USA
